Band 3 Phosphorylation Inhibitors for Sickle Cell Membrane Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for sickle cell disease (SCD) lack a therapeutic agent that effectively inhibits erythrocyte band 3 tyrosine phosphorylation without suppressing youth growth, leading to membrane destabilization and associated complications.

Innovation Solution

Development of a compound (Formula I) that selectively inhibits erythrocyte band 3 tyrosine phosphorylation with high specificity for Syk kinase, minimizing interference with growth factor receptor kinases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a tyrosine kinase inhibitor is used to treat sickle cell disease, then band 3 phosphorylation is inhibited, but growth factor receptor kinases are also suppressed leading to stunted growth in children

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidgrowth suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The compound is designed to selectively inhibit band 3 tyrosine phosphorylation in erythrocytes while sparing growth factor receptor kinases. This is achieved through specific molecular interactions that target the unique structural features of band 3 phosphorylation sites, allowing therapeutic action on sickle cell pathology without affecting growth processes in pediatric patients

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention changes the selectivity parameter of the tyrosine kinase inhibitor by optimizing its chemical structure (Formula I with specific R1, R2, R3 substituents) to differentiate between band 3 kinase and growth factor receptor kinase binding affinities. This parameter optimization allows the compound to achieve therapeutic efficacy against sickle cell disease while maintaining safety for pediatric growth development

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If band 3 phosphorylation is inhibited to stabilize erythrocyte membrane, then microparticle release and hemoglobin escape are reduced, but selective inhibition without affecting growth factor receptors is challenging

Engineering Contradiction:

Improveerythrocyte membrane stabilityVSAvoidcompound selectivity

Core Design Contradiction:

Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The compound structure is segmented into distinct functional groups (R1, R2, R3 substituents on the core structure) that can be independently optimized. This segmentation allows separate optimization of binding affinity for band 3 kinase versus selectivity against growth factor receptor kinases, simplifying the overall drug design process while achieving both membrane stabilization and growth safety

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The compound acts as a selective intermediary that specifically mediates inhibition of band 3 phosphorylation without interfering with growth factor signaling pathways. The molecular structure serves as a bridge between the therapeutic target (band 3 kinase) and the safety requirement (growth factor receptor sparing), enabling selective action through structured molecular recognition

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12473264B2Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof

Publication Date: 2025.11.18 PURDUE RES FOUND

AI summary

Inhibitors of erythrocyte band 3 tyrosine phosphorylation of formula (I), and pharmaceutical salts thereof, are described:wherein R1-R3 are defined herein. Compositions comprising compounds of the formula (I), and methods of using the compounds and compositions comprising the compounds to treat sickle cell diseases are also described.